Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole for chronic pulmonary aspergillosis
2016-003921-40Phase 2Terminated
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isavuconazole in chronic pulmonary aspergillosis (CPA) and aspergillosis, sponsored by Manchester University NHS Foundation Trust. Primary endpoint: Clinical and radiological response after 12 months of therapy. Started Jul 2017; status: terminated.
02
Drugs
isavuconazole
03
Conditions
chronic pulmonary aspergillosis (CPA)aspergillosis
Beyond the preview
Go deeper on 2016-003921-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003921-40.